clifutinib
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started May 18, 2018 (NCT04827069)
Timeline
Indications
Mechanism of action
FLT3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07211165 | Phase 1 | Sep 29, 2025 | Sunshine Lake Pharma Co., Ltd. |
| NCT05454098 | Phase 1 | Nov 30, 2022 | Sunshine Lake Pharma Co., Ltd. |
| NCT05586074 | Phase 3 | Nov 28, 2022 | Sunshine Lake Pharma Co., Ltd., Zhejiang University |
| NCT05133882 | Phase 1/Phase 2 (Phase 2) | Jan 12, 2022 | Sunshine Lake Pharma Co., Ltd., Zhejiang University |
| NCT04827069 | Phase 1 | May 18, 2018 | Sunshine Lake Pharma Co., Ltd., Zhejiang University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunshine Lake Pharma Co., Ltd. | For profit | 5 | 5 | 3 | 2018 |
| Zhejiang University | Academic/Hospital | 3 | 0 | 3 | 2018 |
2 organizations
Page 1 / 1